Just what are the 7-year weight and co-morbidity changes following bariatric surgery?

A multicenter longitudinal research project focused on this very question, studying patients at ten hospitals who had undergone either Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB).

Parameters of the study:

  • The 2,348 subjects were adults who had undergone bariatric surgical procedures between 2006 and 2009.
  • Surgeries were performed at ten U.S. hospitals in six geographically diverse clinical centers.
  • Median age of participants was 45 years for the RYBG, 48 for the LAGB patients.
  • Patient follow-up continued through January of 2015.

Significant findings:

  1. The 7-year mean weight loss was 28.4% with a 3.9% regain after 3 years for gastric bypass patients, and 14.9% mean weight loss with regain of 1.4% after 3 years for banding patients.
  2. The prevalence of dyslipidemia (unhealthy levels of lipid in the blood) was reduced seven years following both procedures.
  3. Diabetes and hypertension prevalence were reduced, with remission of diabetes after seven years 60.2% for gastric bypass and 20.3% for gastric banding.

Meanwhile, the Association of Surgical Technologists cautions O.R. staff that, with morbidly obese patients, positioning can become an issue and “the use of additional foam positioning devices may actually contribute to the development of pressure injuries, due to the patient’s weight compressing the devices. Action Products manufactures Akton® gel positioners, which do not bottom out.

“Metabolic surgery is the best treatment for long-term weight loss maintenance and co-morbidity control, confirm the authors of Nature Reviews Gastroenterology & Hepatology, explaining that “the complex interactions between the gut-brain-endocrine axis, the gut microbiota and bile acid kinetics are postulated to have a role in reducing food intake and improving metabolic control after metabolic surgery.” Authors Sinclair, Brennan, and le Roux go as far as to suggest that “these underlying mechanisms could explain how metabolic surgery could be used as a therapeutic option in certain obesity-relation cancers.”